Mitral Valve Prolapse (MVP) is a common heart valve condition characterized by the improper closing of the valve between the heart's upper and lower left chambers, the atrium and ventricle. In individuals with MVP, the valve's flaps, known as leaflets, bulge or collapse backward into the atrium, causing a regurgitation of blood. While many people with MVP may not experience symptoms, others may encounter chest pain, palpitations, or fatigue. The exact cause of MVP is often unknown, but it can be associated with connective tissue disorders. Diagnosis typically involves echocardiography, which allows visualization of the valve's structure and function. Treatment is often unnecessary for those without symptoms, but in severe cases, medications or, in rare instances, surgery may be recommended to repair or replace the valve. Regular monitoring and consultation with healthcare professionals are essential for managing Mitral Valve Prolapse effectively.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India